British Journal of Cancer · 2020 · 52 citations · 36 references
MedicineBiostatisticsOncologyCancer EpidemiologyEpidemiologic MethodsEpidemiologyAge-period-cohort AnalysisCancer IncidenceCancer RegistriesCancer SurveillanceTemporal Trends In CancerAge-specific Cancer IncidenceAge-specific Incidence PatternsBreast Cancer Molecular SubtypesCancer Registry Data AnalysisCancer Trends By AgeIncidence RateIncidence Trend AnalysisTemporal Trends In Incidence
BACKGROUND: We describe temporal trends in breast cancer incidence by molecular subtypes in Scotland because public health prevention programmes, diagnostic and therapeutic services are shaped by differences in tumour biology. METHODS: Population-based cancer registry data on 72,217 women diagnosed with incident primary breast cancer from 1997 to 2016 were analysed. Age-standardised rates (ASR) and age-specific incidence were estimated by tumour subtype after imputing the 8% of missing oestrogen receptor (ER) status. Joinpoint regression and age-period-cohort models were used to assess whether significant differences were observed in incidence trends by ER status. RESULTS: Overall, ER-positive tumour incidence increased by 0.4%/year (95% confidence interval (CI): -0.1, 1.0). Among routinely screened women aged 50-69 years, we observed an increase in ASR from 1997 to 2011 (1.6%/year, 95% CI: 1.2-2.1). ER-negative tumour incidence decreased among all ages by 2.5%/year (95% CI: -3.9 to -1.1%) over the study period. Compared with the 1941-1959 birth cohort, women born in 1912-1940 had lower incidence rate ratios (IRR) for ER+ tumours and women born in 1960-1986 had lower IRR for ER- tumours. CONCLUSIONS: Future incidence and survival reporting should be monitored by molecular subtypes to inform clinical planning and cancer control programmes.
36
Molecular portraits of human breast tumours
Charles M. Perou, Thérese Sørlie, Michael B. Eisen et al. · Nature · 2000 · 16.3K citations
Permutation tests for joinpoint regression with applications to cancer rates
Hyune-Ju Kim, Michael P. Fay, Eric J. Feuer et al. · Statistics in Medicine · 2000 · 6.1K citations
Multiple significance tests: the Bonferroni method
Martin Bland, Doug Altman · BMJ · 1995 · 3.9K citations · Full text
Medicine, Immunology, Oncology +17
Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer
Gϋnter von Minckwitz, Marion Procter, Evandro de Azambuja et al. · New England Journal of Medicine · 2017 · 1.4K citations · Full text
Medicine, Oncology, Pharmacology +17